piribedil has been researched along with Bewilderment in 1 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Piribedil is a dopamine agonist acting on D2 and D3 central nervous system dopamine receptors." | 2.70 | Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. ( Allain, H; Bentué-Ferrer, D; Gandon, JM; Kleinermans, D; Polard, E; Reymann, JM; Schück, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schück, S | 1 |
| Bentué-Ferrer, D | 1 |
| Kleinermans, D | 1 |
| Reymann, JM | 1 |
| Polard, E | 1 |
| Gandon, JM | 1 |
| Allain, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function[NCT01519856] | 908 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for piribedil and Bewilderment
| Article | Year |
|---|---|
Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers.
Topics: Adult; Attention; Cognition; Confusion; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; | 2002 |